Hoekema L, Castoldi E, Tans G, Girelli D, Gemmati D, Bernardi F, Rosing J
Department of Biochemistry, Cardiovascular Research Institute, Maastricht, Maastricht University, The Netherlands.
Thromb Haemost. 2001 Jan;85(1):75-81.
Carriership of the factor V (FV) gene marked by the R2-haplotype, a series of linked polymorphisms encoding several amino acid changes in FV, is associated with mild resistance to activated protein C (APC) and with an increased risk of thrombosis. We compared the functional properties of normal FV(a) and R2-FV(a) in model systems and in plasma. FV and R2-FV were equally well activated by thrombin and expressed identical cofactor activities in prothrombin activation. Rate constants of APC-catalyzed inactivation of FVa and R2-FVa were similar both with and without protein S. However, significant differences were observed between haemostatic parameters determined in plasma from homozygous carriers of the R2-gene (n = 5) and age-matched non-carriers (n = 19). Plasma from R2-carriers contained significantly lower FV levels and the ratio of the two FV isoforms (FV1 and FV2) was shifted in favor of FV1. The FV2/FV1 ratio was 1.4 (95% CI = 1.3-1.5) in homozygous carriers of R2 and 2.8 (95% CI = 2.5-3.1) in controls (p < 0.00001). In an APC resistance test which quantifies the cofactor activity of FV in APC-catalyzed FVIII(a) inactivation, homozygous R2-carriers had significantly lower (p < 0.00001) APC sensitivity ratios (APCsr = 1.54, 95% CI = 1.48-1.60) than controls (APCsr = 2.17, 95% CI = 2.05-2.28). This indicates that R2-FV has reduced cofactor activity in APC-catalyzed FVIII(a) inactivation. The changes of the relative amounts of FV1 and FV2 in carriers of the R2-gene will result in increased thrombin formation in the presence of APC and may provide a mechanistic explanation for the increased thrombotic risk associated with the R2-haplotype.
由R2单倍型标记的凝血因子V(FV)基因的携带状态,即一系列编码FV中多个氨基酸变化的连锁多态性,与对活化蛋白C(APC)的轻度抵抗以及血栓形成风险增加相关。我们在模型系统和血浆中比较了正常FV(a)和R2-FV(a)的功能特性。FV和R2-FV被凝血酶激活的程度相同,并且在凝血酶原激活中表现出相同的辅因子活性。无论有无蛋白S,APC催化FV a和R2-FV a失活的速率常数都相似。然而,在R2基因纯合携带者(n = 5)和年龄匹配的非携带者(n = 19)的血浆中测定的止血参数之间观察到显著差异。R2携带者的血浆中FV水平显著降低,并且两种FV异构体(FV1和FV2)的比例向有利于FV1的方向偏移。R2纯合携带者中FV2/FV1的比例为1.4(95%置信区间= 1.3 - 1.5),对照组中为2.8(95%置信区间= 2.5 - 3.1)(p < 0.00001)。在一项量化FV在APC催化FVIII(a)失活中的辅因子活性的APC抵抗试验中,R2纯合携带者的APC敏感性比率(APCsr = 1.54,95%置信区间= 1.48 - 1.60)显著低于对照组(APCsr = 2.17,95%置信区间= 2.05 - 2.28)(p < 0.00001)。这表明R2-FV在APC催化FVIII(a)失活中的辅因子活性降低。R2基因携带者中FV1和FV2相对量的变化将导致在存在APC的情况下凝血酶形成增加,并可能为与R2单倍型相关的血栓形成风险增加提供一个机制解释。